AKBA - Akebia Therapeutics, Inc.
1.25
0.030 2.400%
Share volume: 1,916,150
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$1.22
0.03
0.02%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-07-2024 | 03-13-2025 | 05-08-2025 | 08-07-2025 | 11-10-2025 | 02-26-2026 | |
| Assets | |||||||||
| Total Assets | 225.477 M | 220.196 M | 207.142 M | 220.670 M | 310.185 M | 345.595 M | 364.152 M | 376.565 M | |
| Current Assets | 112.944 M | 112.097 M | 100.120 M | 113.831 M | 203.782 M | 234.657 M | 258.336 M | 252.955 M | |
| Inventories | 25.532 M | 23.872 M | 20.493 M | 16.243 M | 19.732 M | 16.708 M | 18.643 M | 15.610 M | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 41.961 M | 39.499 M | 34.019 M | 51.870 M | 113.374 M | 137.308 M | 166.444 M | 184.844 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 3.265 M | 2.895 M | 2.533 M | 2.200 M | 1.904 M | 1.714 M | 1.473 M | 1.222 M | |
| Other Assets | 109.268 M | 105.204 M | 104.489 M | 104.639 M | 104.499 M | 109.224 M | 104.343 M | 122.388 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 225.477 M | 220.196 M | 207.142 M | 220.670 M | 310.185 M | 345.595 M | 364.152 M | 376.565 M | |
| Total liabilities | 252.735 M | 253.950 M | 257.544 M | 269.855 M | 285.604 M | 316.371 M | 322.560 M | 343.955 M | |
| Total current liabilities | 66.487 M | 107.300 M | 65.709 M | 80.914 M | 91.227 M | 118.717 M | 133.379 M | 162.938 M | |
| Accounts Payable | 11.882 M | 10.107 M | 13.494 M | 15.180 M | 12.658 M | 11.554 M | 10.087 M | 21.185 M | |
| Other liabilities | 112.807 M | 108.619 M | 153.480 M | 150.248 M | 147.866 M | 150.592 M | 141.540 M | 132.767 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 30.145 M | 38.031 M | 38.355 M | 38.693 M | 46.511 M | 47.062 M | 47.641 M | 48.250 M | |
| Other liabilities | 112.807 M | 108.619 M | 153.480 M | 150.248 M | 147.866 M | 150.592 M | 141.540 M | 132.767 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -27.258 M | -33.754 M | -50.402 M | -49.185 M | 24.581 M | 29.224 M | 41.592 M | 32.610 M | |
| Common stock | 1.600 B | 1.602 B | 1.605 B | 1.629 B | 1.697 B | 1.701 B | 1.713 B | 1.716 B | |
| Retained earnings | -1.627 B | -1.636 B | -1.656 B | -1.678 B | -1.672 B | -1.672 B | -1.671 B | -1.684 B |